GPla Polymorphisms Are Associated with Outcomes in Patients at High Cardiovascular Risk

Abstract

BackgroundPlatelet membrane glycoprotein receptors mediate thrombus formation. GP Ia/IIa is an essential platelet integrin receptor. Single-nucleotide polymorphisms (SNPs) of the GP Ia/IIa gene alter GP Ia/IIa expression; however, their influence on cardiovascular disease remains unclear. This study aimed to investigate the effect of the GP Ia/IIa SNPs rs1126643 and rs1062535 on clinical outcomes in a large collective including high-risk patients with cardiovascular disease.Methods and resultsGP Ia SNP analysis was performed in 943 patients with symptomatic coronary artery disease. All patients were tracked for all-cause death, myocardial infarction, and ischemic stroke for 360 days. Homozygous carriers of the minor allele showed significantly worse event-free survival when compared with major allele carriers in the complete collective as well as in the subset of high-risk patients (carrying all of the following three risk factors: diabetes type II, hypertension, and hyperlipidemia). There was no significant difference in the subset of low-risk patients (carrying none of the three risk factors).ConclusionsGPla SNPs are associated with cardiovascular prognosis especially in high-risk patients. Identification of GPIa SNPs is of importance to tailor therapies in patients at already high cardiovascular risk.

Homophilic Interaction Between Transmembrane-JAM-A and Soluble JAM-A Regulates Thrombo-Inflammation

“…F11R -SNV (rs2774276, rs2481084, rs3737787, rs790056) analysis was performed in consecutive symptomatic CAD 20 patients (n = 833). Chronic coronary syndrome (CCS) and acute coronary syndrome (ACS) were defined as explained previously.…”

“…Chronic coronary syndrome (CCS) and acute coronary syndrome (ACS) were defined as explained previously. 20 All patients were admitted to the Department of Cardiology and Angiology, University Hospital Tübingen, and gave written informed consent. The study was approved by the institutional ethics committee (270/2011BO1, 237/2018BO2), and complied with the Declaration of Helsinki and good clinical practice guidelines.…”

C5 Variant rs10985126 is Associated with Mortality in Patients with Symptomatic Coronary Artery Disease

“…Minor allele frequencies of the analyzed C5 variants are provided in Table 3. 31,32 Enzyme-Linked Immunosorbent Assay (ELISA)…”

From Snake Venom’s Disintegrins and C-Type Lectins to Anti-Platelet Drugs

“…In particular, drugs that target platelets involved in the formation of thrombi would specifically affect atherosclerotic lesions but with a reduced risk of bleeding side effects. Therefore, α2β1 integrin is a good target for novel antithrombotic therapy because it is associated with high cardiovascular risk of stroke and myocardial infarction [46] and since its overexpression is associated with pathological clot formation whereas its absence does not cause severe bleeding. α2β1 is expressed at low levels in a mildly prolonged bleeding time clinical situations, which is quite different from the profound bleeding disorder observed in deficiency of the platelet fibrinogen receptor integrin αIIbβ3 (Glanzmann’s thrombasthenia) [47].…”